A039200 Stock Overview
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Oscotec Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩40,100.00 |
52 Week High | ₩45,850.00 |
52 Week Low | ₩18,000.00 |
Beta | 1.16 |
11 Month Change | 12.32% |
3 Month Change | -4.52% |
1 Year Change | 83.52% |
33 Year Change | 28.73% |
5 Year Change | 101.00% |
Change since IPO | 436.45% |
Recent News & Updates
Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?
Aug 07Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?
Apr 26Recent updates
Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?
Aug 07Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?
Apr 26Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?
Feb 23If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns
Jan 19Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?
Dec 15Shareholder Returns
A039200 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 0.8% | 2.9% | 0.1% |
1Y | 83.5% | 38.8% | 6.3% |
Return vs Industry: A039200 exceeded the KR Pharmaceuticals industry which returned 38.8% over the past year.
Return vs Market: A039200 exceeded the KR Market which returned 6.3% over the past year.
Price Volatility
A039200 volatility | |
---|---|
A039200 Average Weekly Movement | 10.5% |
Pharmaceuticals Industry Average Movement | 6.9% |
Market Average Movement | 6.8% |
10% most volatile stocks in KR Market | 12.2% |
10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A039200's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A039200's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 54 | James Kim | oscotec.com |
Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in Phase 1a/1b clinical trials for the treatment of Alzheimer’s disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide.
Oscotec Inc. Fundamentals Summary
A039200 fundamental statistics | |
---|---|
Market cap | ₩1.54t |
Earnings (TTM) | -₩26.31b |
Revenue (TTM) | ₩4.62b |
333.8x
P/S Ratio-58.6x
P/E RatioIs A039200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A039200 income statement (TTM) | |
---|---|
Revenue | ₩4.62b |
Cost of Revenue | ₩2.24b |
Gross Profit | ₩2.38b |
Other Expenses | ₩28.68b |
Earnings | -₩26.31b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -684.36 |
Gross Margin | 51.48% |
Net Profit Margin | -569.65% |
Debt/Equity Ratio | 36.5% |
How did A039200 perform over the long term?
See historical performance and comparison